LGVN Longeveron

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

Live conference call on Monday, November 14 at 8:30 a.m. EST

MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company’s financial results and provide a corporate update on the same day at 8:30 a.m. EST.

Dial-in Number

U.S. Dial-in Number: 844-200-6205

Canada Dial-in Number: 833-950-0062

All Other Locations Dial-in Number: 929-526-1599

Access code: 982246

U.S. Replay Dial-in Number: 866-813-9403

Canada Replay Dial-in Number: 226-828-7578

All Other Locations Dial-in Number: 44-204-525-0658

Conference ID: 329442

An audio webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at . A replay of the call will be available on the Longeveron website shortly after completion of the call.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at .

Investor Contact:

Elsie Yau

Stern IR, Inc.

212-698-8700



EN
07/11/2022

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron Announces Closing of Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) --...

7h / 49m 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Private Placement of up to $30 Million

Longeveron Announces Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron...

March 10, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell...

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in , a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the phys...

February 25, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue...

February 13, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance A...

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron’s laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch